Cancer pain
Conditions
Interventions
Experimental(Arm1):treated with routine analgesics and Han’s Accupoint
Placebo Comparator (Arm 2):treated with routine analgesics and MOCK-HANS
Sponsors
the First Affiliated Hospital of General Hospital of PLA
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed malignancies (clinical diagnosis was adequate for hepatocellular carcinoma and pancreatic cancer); 2. 18-80 years of age; 3. KPS score>=40; 4. The expected survival time >=1 month; 5. Persistent cancer pain >=1 month; 6. Ongoing opioid therapy and resulted opioid tolerance (According to the U.S Food and Drug Administration, "patients considered opioid tolerant are those who are taking at least: 60mg oral morphine/day, 25mcg transdermal fentanyl/hour, 30mg oral oxycodone/day, 8mg oral hydromorphone/day, 25mg oxymorphone/day, or an equivalent analgesic dose of another opioid for one week or longer".); 7. Conscious, able to read, write and complete the survey questionnaires; 8. The patients themselves agreed to participate in this study.
Exclusion criteria
Exclusion criteria: 1. Pacemaker; 2. Pregnancy; 3. High fever; receiving systemic chemotherapy or local radiation of the pain (1) Pregnant or lactating women; (2) Hyperpyrexia; (3) Cognitive impairment or communication disorders; (4) Severe functional abnormalities of the heart, liver and kidneys; (5) Radiotherapy of the pain sites, systemic chemotherapy or other anticancer therapies 1 week before enrollment and during the study; (6) Placement of pacemakers; (7) Local infective inflammation and ulcers or dysesthesia/paresthesia at the electrode attachment skin sites; (8) Patient with poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pain intensity and daily function interfered assessed by BPI-C at basline and on the 8th and the 15th days;Opioid analgesic usage (total dose in morphine equivalents); | — |
Secondary
| Measure | Time frame |
|---|---|
| the frequency of the breakthrough (BT) pain;quality of life assessed by using EORTC-C30;anxiety and depression assessed by using SADS;side effects of HANS; | — |
Countries
China
Contacts
Public ContactXiao Wenhua
Department of Medical Oncology, the First Affiliated Hospital of Chinese PLA General Hospital
Outcome results
None listed